New derivatives of licochalcone A were synthesized and evaluated for their potential anticancer activities. Compounds 6 ((E)-N-(4-(3-(5-bromo-4-hydroxy-2-methoxy phenyl) acryloyl) phenyl)-4-isopropylbenzamide) and 8 (1-(3-dimethylamino-phenyl)-3-(2-trifluoromethyl-phenyl)-propenone) showed potent activity against the screened cancer cell lines with that of compound 6 ranging from 6.9 ± 0.2 μM to 22.9 ± 3.1 μM, and that of compound 8 from 4.2 ± 0.5 μM to 11.8 ± 0.7 μM. Both compounds showed stronger cytotoxicity than that of licochalcone A. These two candidates have very different substituents and could be considered as promising lead compounds for further development of potent anticancer agents.
The development of cancer depends more importantly on lifestyle and environmental factors rather than inherited genetic defects [1] . Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of all oral cancers which cause high morbidity and mortality. OSCC is caused by smoking, drinking alcohol, poor dental and oral hygiene and infection with human papillomavirus [2] . Diagnosis and treatment of malignant pleural mesothelioma (MPM) is difficult. MPM originates in the lining of the lungs primarily due to exposure to high levels of asbestos [3] .Main treatments for oral cancers and MPM are surgical excision, radiotherapy and chemotherapy, employed alone or in combination [4] . During the course of identifying new anticancer agents from various sources such as microorganisms, plants and animals, we found licochalcone A (Lico A) from Glycyrrhiza inflata [5] . Although various bioactivities of licochalcone A (1) have been demonstrated [6] [7] [8] , its anticancer mechanisms in oral cancer and MPM are still under investigation [3, [9] [10] [11] .In this study, we identified prospective anticancer candidates through modifications of Lico A (Figure 1 ). It was reported that Lico A has a protein tyrosine phosphatase 1B (PTP1B) inhibitory effect [12] and replacement of the substituted allyl group in LicoA with bromine provides a bromo-retrochalcone that has much better activity than allyl retrochalcones as a PTP1Binhibitor [13] . PTP1B is a promising drug target for the treatment of type 2 diabetes and obesity and it is also involved in cancer [14] . Hence, we screened five bromo-retrochalcones with good PTP1B inhibitory effect against malignant pleural mesothelioma cells (MSTO) and two types of human oral squamous cell cancer cell lines (HN22, HSC4) ( Figure 2 ). Compounds 2 and 4 showed similar activity against the MSTO cell line, and compounds 2, 4, and 5 exhibited better effect than Lico A. In our previous report, compound 4 was found to be a partial PPARα/γ dual agonist, as well as a PTP1B inhibitor with improved insulin sensitivity [15] . Of the tested compounds, compound 6 with 4-isopropylbenzyl amide, was 5 times more potent in MSTO, 5 times more potent in HN22, and 2 times more potent in HSC4 than Lico A. To design a structure with better anticancer effect, we introduced trifluoromethyl substituents in the B-ring instead of the methoxyl group, and named it trifluoromethyl-retrochalcone. A number of 2-substituted and disubstituted analogues were prepared ( Table 1 ). The synthetic pathway is shown in Figure 3 . Aldol condensation of substituted acetophenones with trifluoromethyl substituted benzaldehydes in the presence of KOH in ethanol provided trifluoromethyl-retrochalcones (7-22) at room temperature [13, 16] . As shown in Table 2 , trifluoromethyl-retrochalcones with tetrazole in the A-ring (17-22) showed less anticancer activity than Lico A, but these compounds exhibited antimicrobial activity against Staphylococcus aureus and MRSA strains (data not shown). Compounds 7, 8 and 11 in the MSTO cell line, compounds 8, 9, and 12 in the HN22 cell line, and compounds 7, 8, and 11 in the HSC4 cell line showed similar or better activity than Lico A, respectively. Generally compounds with amine in the A ring showed good anticancer activity. Especially, compound 8,with dimethylamine at the meta position in the A-ring, showed 3 times more activity than Lico A against the MSTO cell line and had the most potent effect in HN22 and HSC4 cell lines. In the present study, new derivatives of licochalcone A were synthesized and evaluated for their potential anticancer activities. Compounds 6 and 8 showed more potent anticancer activity against the screened cancer cell lines than licochalcone A. These results show that bromo-retrochalcone and trifluoromethyl-retrochalcone can be agents against malignant pleural mesothelioma and oral squamous cell cancer. Further investigations of compounds 6 and 8 with respect to their anticancer mechanisms and structure-activity relationship studies are currently being performed and the results will be published in due course.
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